Skip to main content

Table 1 Characterististics of groups of study subjects

From: Gene susceptibility identification in a longitudinal study confirms new loci in the development of chronic obstructive pulmonary disease and influences lung function decline

Variable

Subjects in 1992

Subjects in2010

Subjects of Cases form controls

Rural replication subjects

Urban replication subjects

Cases

Controls

Cases

Controls

Cases

Controls

Cases

Controls

Cases

Controls

No. of subjects

306

743

409

611

112

587

374

377

541

560

Age (±SD) (yr)

50.81 ± 6.17

49.19 ± 6.19

67.58 ± 7.12

66.93 ± 6.20

66.70 ± 6.24

66.58 ± 6.35

62.46 ± 9.28

61.39 ± 10.13

65.73 ± 9.13

64.55 ± 9.86

Male (%)

286 (93.5%)

684(92.1%)

385(94.1%)

566(92.6%)

106(94.6%)

546(93.0%)

304(81.3%)

309(82.0%)

443(81.9%)

445(79.5%)

Pack-years (±SD)

28.74 ± 16.57

25.58 ± 15.76

40.42 ± 24.40

43.29 ± 34.75

37.75 ± 18.77

40.29 ± 32.95

26.64 ± 21.13

22.74 ± 20.62

41.22 ± 48.42

45.68 ± 20.14

Post-FEV1 (±SD)

2.03 ± 0.52

2.82 ± 0.57

1.58 ± 0.62

2.43 ± 0.57

1.91 ± 0.61

2.45 ± 0.53

1.54 ± 0.70

2.59 ± 0.76

1.15 ± 0.58

2.31 ± 0.69

Post-FEV1%pre (±SD)

63.36 ± 27.01

108.15 ± 32.9

54.14 ± 22.03

97.23 ± 27.29

60.98 ± 14.43

98.01 ± 25.19

66.11 ± 25.19

106.8 ± 19.71

46.63 ± 20.26

121.3 ± 15.79

Post-FEV1/FVC ratio (±SD)

60.18 ± 7.36

78.70 ± 6.19

57.28 ± 9.48

78.22 ± 5.79

61.71 ± 7.15

78.22 ± 5.79

55.04 ± 11.46

78.70 ± 6.17

50.95 ± 12.47

82.34 ± 8.19